They are designed to enhance the body’s capability to decrease blood glucose when it is elevated by acting on the organic hormones, incretins, increasing insulin production thereby, and by reducing the liver’s production of glucose. The release of ONGLYZA is expected to begin in the 4th quarter of 2009.. Bristol-Myers Squibb and AstraZeneca receive advertising authorisation for ONGLYZA in European countries Bristol-Myers Squibb Organization and AstraZeneca announced today that the European Commission provides granted marketing authorisation for ONGLYZATM in the 27 countries of europe.Pterostilbene provides superior biological activity, better oral bioavailability and metabolizes even more slowly in the body than additional antioxidant polyphenols , leading to even more prolonged antioxidant activity. The scholarly study, a double-blind, placebo-controlled trial, included 80 adults averaging 54 years with high cholesterol . Most participants were females and some had been diagnosed with high blood circulation pressure . The mean typical baseline systolic blood circulation pressure was 127.4 mmHg and the mean average baseline diastolic BP was 79.3 mmHg. The American Heart Association guidelines state that >119 mmHg systolic BP and >79 mmHg diastolic BP are categorized as pre-hypertensive. Twice daily, participants received high dosages of pterostilbene, low dosages of pterostilbene, pterostilbene with grape extract , or placebo.